Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Understanding How Liver X Receptor Beta Antagonism Alleviates Glucocorticoid Mediated Adipose Tissue Dysfunction
FY 2022-23
Summary
Synthetic glucocorticoids (GC) are used therapeutically as potent and effective anti-inflammatory drugs. Globally, 2% of the population is prescribed long-term GC therapy for treatment of conditions such as allergy, organ transplant rejection, and rheumatoid arthritis. However, long-term exposure to GCs increases the incidence of metabolic side effects, such as diabetes and obesity, in part through adipose tissue (AT) dysfunction. GCs suppress brown adipose tissue (BAT) function and disrupt white adipose tissue (WAT) homeostasis. Adipose-specific liver X receptor beta (LXRb) knockout mice and liver-specific LXRb knockout mice have each been shown to be resistant to some aspects of GC-induced dysfunction, suggesting an interplay between the LXRb and the glucocorticoid receptor (GR). My first priority will be to delineate whether loss of LXRb in WAT or BAT is critical to protect against GC-induced AT dysfunction. I will generate a mouse strain with BAT-specific deletion of LXRb and challenge it with GC treatment. My second goal will be to understand organ crosstalk between liver and AT and determine how this is potentiated by LXRb in GC-treated mice. Finally, I will investigate the molecular mechanisms underlying the interplay between GR and LXRb on specific genomic regulatory regions, using chromatin immunoprecipitation. Our mechanistic studies will expand our knowledge on the physiological and molecular mechanisms involved in GR and LXR interplay, which could open more avenues for therapeutic strategies. Our research will also help to determine the degree of protection provided by the different adipose tissue depots and provide insight into the synergistic role of LXRb in liver and fat to mitigate GC-induced metabolic side effects.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486196
Name
Shah Hetvi B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding How Liver X Receptor Beta Antagonism Alleviates Glucocorticoid Mediated Adipose Tissue Dysfunction
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adipose Tissue; Adipose Tissue Dysfunction; Diabetes; Glucocorticoid; Liver; Liver X Receptor Beta; Metabolic Diseases; Metabolism; Nuclear Receptor
Abstract
Synthetic glucocorticoids (GC) are used therapeutically as potent and effective anti-inflammatory drugs. Globally, 2% of the population is prescribed long-term GC therapy for treatment of conditions such as allergy, organ transplant rejection, and rheumatoid arthritis. However, long-term exposure to GCs increases the incidence of metabolic side effects, such as diabetes and obesity, in part through adipose tissue (AT) dysfunction. GCs suppress brown adipose tissue (BAT) function and disrupt white adipose tissue (WAT) homeostasis. Adipose-specific liver X receptor beta (LXRb) knockout mice and liver-specific LXRb knockout mice have each been shown to be resistant to some aspects of GC-induced dysfunction, suggesting an interplay between the LXRb and the glucocorticoid receptor (GR). My first priority will be to delineate whether loss of LXRb in WAT or BAT is critical to protect against GC-induced AT dysfunction. I will generate a mouse strain with BAT-specific deletion of LXRb and challenge it with GC treatment. My second goal will be to understand organ crosstalk between liver and AT and determine how this is potentiated by LXRb in GC-treated mice. Finally, I will investigate the molecular mechanisms underlying the interplay between GR and LXRb on specific genomic regulatory regions, using chromatin immunoprecipitation. Our mechanistic studies will expand our knowledge on the physiological and molecular mechanisms involved in GR and LXR interplay, which could open more avenues for therapeutic strategies. Our research will also help to determine the degree of protection provided by the different adipose tissue depots and provide insight into the synergistic role of LXRb in liver and fat to mitigate GC-induced metabolic side effects.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shah, Hetvi B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~